S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

InnovAge to Pay $36 Million to Settle Care Allegations

InnovAge Holding will pay $36 million to resolve allegations that it failed to arrange timely medical services and specialist referrals for senior patients between 2016 and 2022, the Justice Department said. The settlement covers claims under the federal False Claims Act and state laws, but is not a determination of liability.

InnovAge to Pay $36 Million to Settle Care Allegations

The Denver-based company receives Medicare and Medicaid funding to provide healthcare to seniors at centers across several states. According to the Justice Department, InnovAge did not maintain adequate specialist provider networks and often failed to schedule appointments or consultations promptly in fields including oncology, cardiology, surgery and neurology. The department said those practices meant the company did not meet requirements of the dual Medicare-Medicaid program.

InnovAge said it had worked closely with the Centers for Medicare and Medicaid Services and state government partners, while investing to strengthen its clinical operations, compliance infrastructure and care delivery. A company spokesperson said the settlement resolves historical allegations without an admission of wrongdoing and allows InnovAge to continue focusing on care for the frail seniors it serves.

Under the agreement, about $25.7 million will go to the U.S. and a combined $10.3 million to Colorado, California, New Mexico and Virginia.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!